Brief: Biogen Provides Regulatory Update On High Dose Regimen Of Nusinersen
23/09/2025 23:14
Sept 23 (Reuters) - Biogen Inc BIIB.O: BIOGEN PROVIDES REGULATORY UPDATE ON HIGH DOSE REGIMEN OF NUSINERSEN BIOGEN INC - FDA REQUESTS UPDATE TO CMC MODULE IN BIOGEN'S SNDA BIOGEN INC - CRL DID NOT CITE DEFICIENCIES IN CLINICAL DATA FOR HIGH DOSE REGIMEN BIOGEN INC - TO RESUBMIT APPLICATION PROMPTLY Source text: ID:nGNX3XKGR4 Further company coverage: BIIB.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Ionis Pharmaceuticals
See all newsAnalysis: US prices for new drugs fell in 2025 as fewer costly gene therapies were launched
Brief: Ionis Announces License Agreement With Recordati For Zilganersen In Alexander Disease (Axd) In All Countries Outside The U.S.
Brief: Ionis Pharmaceuticals Says FDA Approved Tryngolza For Severe Hypertriglyceridemia
Brief: FDA Approves Treatment To Reduce Risk Of Acute Pancreatitis In Adults With Severe Hypertriglyceridemia
Brief: Ionis Announces Appointment Of Ludwig Hantson, Ph.D. To Board Of Directors